Axonics (AXNX) Stock Price, News & Analysis

Company Overview

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

Key Stats

• Today's Range: $70.98 to $70.98
• 50-Day Range: $69.66 to $70.98
• 52-Week Range: $67.90 to $71.05
• Volume: N/A
• Average Volume: 437,262 shs
• Market Capitalization: $3.63 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Axonics Stock Analysis - MarketRank™

Axonics scored higher than 28% of companies evaluated by MarketBeat, and ranked 813th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Axonics.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 300.00%

Earnings Growth

Earnings for Axonics are expected to grow by 300.00% in the coming year, from $0.22 to $0.88 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Axonics is -591.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Axonics is -591.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Axonics has a P/B Ratio of 5.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for AXNX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Axonics does not currently pay a dividend.

Dividend Growth

Axonics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.1 / 5
• Environmental Score: -1.38

Short Interest

There is no current short interest data available for AXNX.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for AXNX on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Axonics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.85% of the stock of Axonics is held by insiders.

Percentage Held by Institutions

99.48% of the stock of Axonics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AXNX Stock Analysis - Frequently Asked Questions

How were Axonics' earnings last quarter?

Axonics, Inc. (NASDAQ:AXNX) released its earnings results on Thursday, November, 7th. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.05. The firm's revenue was up 24.8% on a year-over-year basis.

When did Axonics IPO?

Axonics (AXNX) raised $100 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

What other stocks do shareholders of Axonics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Axonics investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), NVIDIA (NVDA), TotalEnergies (TTE) and The RMR Group (RMR).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 7/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:AXNX
• CIK: 1603756
• Web: www.axonics.com
• Phone: (949) 396-6322
• Fax: 949-396-6321
• Employees: 610
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 322.64
• P/E Growth: N/A
• Net Income: -$6.09 million
• Net Margins: -1.31%
• Pretax Margin: -0.70%
• Return on Equity: 0.36%
• Return on Assets: 0.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.16
• Quick Ratio: 6.40

Sales & Book Value

• Annual Sales: $366.38 million
• Price / Sales: 9.90
• Cash Flow: $0.13 per share
• Price / Cash Flow: 561.96
• Book Value: $12.59 per share
• Price / Book: 5.64

Miscellaneous

• Outstanding Shares: 51,110,000
• Free Float: 50,163,000
• Market Cap: $3.63 billion
• Optionable: Optionable
• Beta: 0.82